


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) ~~The use~~ A method of treating tumors comprising administering to a subject in need thereof an effective amount of a compound of general formula (I):



(I)

wherein X⁺ is selected from the group consisting of N⁺(R₁, R₂, R₃) and P⁺(R₁, R₂, R₃), wherein R₁, R₂ and R₃, which are the same or different, are selected from the group consisting of hydrogen and C₁-C₉ straight or branched alkyl groups,

-CH=NH(NH₂), -NH₂, -OH; or two or more R₁, R₂ and R₃, together with the nitrogen atom which they are linked to, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic system; with the proviso that at least one of R₁, R₂ and R₃ is different from hydrogen;

Z is selected from

OR₄,

-OCOOR₄,

-OCONHR₄,

-OCSNHR₄,

-OCSOR₄

-NHR₄,

-NHCOR₄,
-NHCSR₄,
-NHCOOR₄,
-NHCSOR₄,
-NHCONHR₄,
-NHCSNHR₄,
-NHSOR₄,
-NHSONHR₄,
-NHSO₂R₄,
-NHSO₂NHR₄,
- SR₄,

wherein R₄ is a C₂-C₂₀ saturated or unsaturated, straight or branched alkyl group; Y- is selected from the group consisting of -COO-, PO₃H, -OPO₃H-, tetrazolate-5-yl; salts, enantiomers and racemic mixtures thereof, for the preparation of an antitumor medicament.

2. (Currently Amended) The ~~[[use]]~~method according to claim 1 ~~[[of a]]~~wherein in the compound of formula (I), ~~wherein~~ independently of one another,

- X is trimethylammonium or a group N⁺(R₁, R₂, R₃) wherein two or more R₁, R₂ and R₃, together with the nitrogen atom which they are linked to, form a heterocyclic system, which is selected from morpholinium, pyridinium, pyrrolidinium, quinolinium and quinuclidinium;
- R₄ is selected from heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and eicosyl;

- Z is a ureido (-NHCONHR₄) or carbamate (-NHCOR₄, -OCONHR₄) group.

3. (Currently Amended) The ~~[[use]]~~method according to claim 2 ~~[[of a]]~~wherein the compound ~~[[which]]~~ is selected from the group consisting of

- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate;
- R,S-4-quinuclidinium-3-(tetradecyloxycarbonyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-oxybutyric acid chloride;
- R,S-4-trimethylphosphonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(octyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-octyloxybutyrate;
- R,S-4-trimethylammonium-3-tetradecyloxybutyrate;
- R,S-1-guanidinium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;
- R,S-1-trimethylammonium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;
- R,S-3-quinuclidinium-2-(tetradecyloxycarbonyl)-oxy-1-propanephosphonate monobasic;
- R,S-3-trimethylammonium-2-(nonylaminocarbonyl)-oxy-1-propanephosphonate monobasic;
- R,S-3-pyridinium-2-(nonylaminocarbonyl)-oxy-1-propanephosphonic acid chloride;
- R-4-trimethylammonium-3-(tetradecylcarbamoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(undecylcarbamoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(heptylcarbamoyl)-aminobutyrate;

- R,S-4-trimethylammonium-3-(nonylthiocarbamoyl)-aminobutyrate;
- R-4-trimethylammonium-3-(noncarbamoyl)-aminobutyrate;
- S-4-trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate;
- S-4-trimethylammonium-3-(tetradecylcarbamyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-tetradecylaminobutyrate;
- R,S-4-trimethylammonium-3-octylaminobutyrate;
- R,S-4-trimethylammonium-3-(decansulfonyl)aminobutyrate;
- R,S-4-trimethylammonium-3-(nonylsulfamoyl)aminobutyrate;
- S-4-trimethylammonium-3-(dodecansulfonyl)aminobutyrate;
- R-4-trimethylammonium-3-(dodecansulfonyl) aminobutyrate;
- S-4-trimethylammonium-3-(undecylsulfamoyl)aminobutyrate;
- R-4-trimethylammonium-3-(undecylsulfamoyl)aminobutyrate;
- R-4-trimethylammonium-3-(dodecylcarbamoyl) aminobutyrate;
- R-4-trimethylammonium-3-(10-phenoxydecylcarbamoyl)aminobutyrate; and
- R-4-trimethylammonium-3-(trans- β -styrenesulfonyl)aminobutyrate.

4. (Currently Amended) The ~~use~~method according to claim ~~[[3]]~~1, ~~[[of]]~~wherein the compound is R-4-trimethylammonium-3- (tetradecylcarbamoyl)-aminobutyrate.

5. (Currently Amended) The ~~use of a compound (I) according to claim 1 for the preparation of an antitumor medicament for the treatment of~~method of claim 1 wherein leukaemias ~~[[and]]~~or hepatocarcinomas are treated.

6. (Previously Presented) A therapeutic preparation containing a compound according to claim 1 in combination with an antitumor agent selected from cytotoxic or cytostatic compounds, antimetabolites, hormone antagonists, alkaloids, antibiotics, in particular antracyclines,

alkylating agents, peptides, agents modifying the biological response, cytokines, for simultaneous separate or sequential administration to a tumor patient.

7. (Currently Amended) A preparation according to claim 6, containing a combination of

a compound ~~according to anyone of claims 1-4 of claim 1~~ and an antracycline.

8. (original) A preparation according to claim 7, wherein the antracycline is doxorubicin.